Royal Bank of Canada Has $142.88 Million Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• Royal Bank of Canada reduced its stake in Edwards Lifesciences Corporation by 13.8% during Q1, now owning approximately $142.88 million in shares.
• Multiple hedge funds have recently acquired new positions in Edwards Lifesciences, contributing to institutional investors owning 79.46% of the company’s stock.
• Edwards Lifesciences reported a quarterly EPS of $0.67, exceeding estimates, and projected future earnings guidance between 0.540-0.60 EPS for Q3 2025.

Royal Bank of Canada cut its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 13.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,971,339 shares of the medical research company's stock after selling 316,342 shares during the period. Royal Bank of Canada owned 0.34% of Edwards Lifesciences worth $142,880,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $26,000. Vega Investment Solutions bought a new position in Edwards Lifesciences in the fourth quarter valued at approximately $27,000. SouthState Corp acquired a new stake in Edwards Lifesciences during the 1st quarter worth $27,000. Global X Japan Co. Ltd. grew its holdings in Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after acquiring an additional 216 shares during the period. Finally, Tradewinds Capital Management LLC raised its position in shares of Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after acquiring an additional 205 shares during the last quarter. Institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $15,565,087. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,014 shares of company stock valued at $1,698,844. Company insiders own 1.29% of the company's stock.

Analyst Ratings Changes

EW has been the topic of several recent research reports. William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Wall Street Zen raised Edwards Lifesciences from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. Truist Financial raised their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the stock a "hold" rating in a report on Friday, July 25th. Barclays upped their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Finally, Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of "Moderate Buy" and a consensus price target of $85.90.

Edwards Lifesciences Stock Down 0.1%

NYSE EW traded down $0.07 during trading hours on Friday, reaching $80.89. 2,283,330 shares of the company's stock were exchanged, compared to its average volume of 3,558,037. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company has a market capitalization of $47.49 billion, a price-to-earnings ratio of 11.64, a price-to-earnings-growth ratio of 3.90 and a beta of 1.07. The company's 50-day moving average is $78.77 and its two-hundred day moving average is $75.21. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business's revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.